Clinical Trial: CBD Offsets THC-Induced Anxiety

Maastricht, The Netherlands: Subjects who consume cannabis containing equal amounts of THC and CBD report experiencing less anxiety than they do after consuming THC-dominant cannabis, according to trial data published in the journal Psychopharmacology.

Dutch investigators assessed perceived anxiety levels in a cohort of 26 subjects following single doses of vaporized cannabis. Subjects vaporized cannabis samples that were either high in THC (13.75 mgs), high in CBD (13.75 mgs), contained equal amounts of both CBD and THC, or that contained no cannabinoids.

Investigators reported that THC-dominant and THC/CBD equivalent samples significantly increased participants’ self-rated state of anxiety compared to placebo, but subjects reported less anxiety after consuming the latter. Specifically, they reported, “Combined treatment of THC and CBD delayed the onset of … anxiety, reduced its magnitude and shortened its duration compared to inhalation of THC alone.”

The study’s findings are consistent with those of prior studies documenting CBD’s anxiolytic effects, and determining that subjects who consume cannabis flowers containing equal ratios of THC and CBD are less likely to report experiencing adverse effects, such as feelings of paranoia. 

Authors concluded: “The present study showed that cannabis containing equivalent concentrations of THC and CBD induces less self-rated … anxiety compared to THC-only cannabis in healthy volunteers. … The THC/CBD combination might be more favorable in clinical settings, and it may be a reasonable public health strategy to encourage cannabis breeds containing THC/CBD mixtures where recreational use of cannabis is now legal.”

Full text of the study, “Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis,” appears in Psychopharmacology.